Prachee Avasthi (L) and Seemay Chou (R), Founders of Arcadia
April 27, 2022 05:18 AM EDTUpdated May 4, 04:13 PM
People
Discovery
In Focus

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

Jason Mast

Editor

It’s rare, though far from unheard of, for scientists to leave prestigious academic appointments. But Seemay Chou’s departure made a larger splash than most.

One cool, cloudy San Francisco afternoon last September, she hit publish on a Medium post titled “Why I am building Arcadia.” It doubled as a public resignation letter from her professorship at UCSF, where she was just months from tenure, and a roadmap to the grand $500 million experiment she planned next.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

SPONSORED
October 3, 2022 06:00 AM EDT

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

Noël Brown

Head of US Biotechnology Investment Banking, RBC Capital Markets

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)
October 4, 2022 06:00 AM EDTUpdated 11:21 AM
People
Pharma
In Focus

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Jared Whitlock

Features Editor

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Fireside chat between Hal Barron and John Carroll, UKBIO19
October 5, 2022 07:38 AM EDT
Bioregnum

It’s time we talked about bio­phar­ma — live in Lon­don next week

John Carroll

Editor & Founder

Zoom can only go so far. And I think at this stage, we’ve all tested the limits of staying in touch — virtually. So I’m particularly happy now that we’ve revved up the travel machine to point myself to London for the first time in several years.

Whatever events we have lined up, we’ve always built in plenty of opportunities for all of us to get together and talk. For London, live, I plan to be right out front, meeting with and chatting with the small crowd of biopharma people we are hosting on October 12 at Silicon Valley Bank’s London headquarters. And there’s a lengthy mixer at the end I’m most looking forward to, with several networking openings between sessions.

Car­olyn Bertozzi (Illustration: Assistant editor Kathy Wong for Endpoints News)
October 5, 2022 07:43 AM EDTUpdated 11:03 AM
People

Car­olyn Bertozzi, re­peat biotech founder and launch­er of a field, shares in chem­istry No­bel win

Kyle LaHucik

Associate Editor

Carolyn Bertozzi, predicted by some to become a Nobel laureate, clinched one of the world’s top awards in the wee hours of Wednesday, winning the Nobel Prize in Chemistry alongside a repeat winner and a Copenhagen researcher.

The Stanford professor, Morten Meldal of University of Copenhagen and 2001-awardee K. Barry Sharpless of Scripps shared the prize equally. The Nobel is sometimes split in quarters and/or halves.

October 4, 2022 10:00 AM EDTUpdated 9 hours ago
Manufacturing

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Zachary Brennan

Senior Editor

Takeda on Tuesday morning made an announcement that almost 3,000 people with the rare disease known as hypoparathyroidism were fearing.

Due to unresolved supply issues and manufacturing woes, Takeda said it will cut its losses and discontinue its hypoparathyroidism drug, known as Natpara (parathyroid hormone), halting all manufacturing of the drug by the end of 2024, but the entire inventory will be available until depleted or expired, a company spokesperson said via email.

Pfizer and BioNTech's original Marvel comic book links evolving Covid vaccine science to Avengers' evolving villain-fighting tools.(Source: Pfizer LinkedIn post)
October 5, 2022 02:23 PM EDT
Pharma
Marketing

Pfiz­er, BioN­Tech part­ner with Mar­vel for Avengers and Covid-fight­ing com­ic book

Beth Snyder Bulik

Senior Editor

Pfizer and BioNTech are collaborating with Marvel to celebrate “everyday” people getting Covid-19 vaccines in a custom comic book.

In the “Everyday Heroes” digital comic book, an evolving Ultron, one of the Avengers’ leading villains, is defeated by Captain America, Ironman and others. The plotline and history of Ultron is explained by a grandfather who is waiting with his family at a clinic for Covid-19 vaccinations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

October 5, 2022 11:28 AM EDTUpdated 06:04 PM
FDA+

FDA+ roundup: Ad­comm date set for Cy­to­ki­net­ics heart drug; New gener­ic drug guid­ance to re­duce fa­cil­i­ty de­lays

Zachary Brennan

Senior Editor

The FDA has set Dec. 13 as the day that its Cardiovascular and Renal Drugs Advisory Committee will review Cytokinetics’ potential heart drug, setting up a key vote ahead of a Feb. 28, 2023 PDUFA date.

The drug, known as omecamtiv mecarbil, read out its first Phase III in November 2020, hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as the key to breaking into the market, failing to significantly differ in reducing cardiovascular death from placebo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Robert Arch, OncoSec Medical CEO
October 5, 2022 07:21 AM EDT
People
R&D

Pen­ny stock, Mer­ck part­ner lays off 45% of staff to reach PhII read­out by ear­ly 2023

Max Gelman

Senior Editor

Another biotech is feeling the chill of the bear market, laying off staff in an effort to preserve cash.

Cancer immunotherapy startup OncoSec Medical announced Tuesday evening it would lay off about 45% of its workforce, or 18 employees, it estimated in an SEC filing. OncoSec made the move to better position the company to complete a Phase II trial for its sole program in melanoma, CEO Robert Arch said in a statement.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

October 5, 2022 03:20 PM EDT
Pharma
Law

Eli Lil­ly and Te­va pre­pare for court bat­tle over mi­graine med ri­val­ry

Nicole DeFeudis

Editor

It looks like Eli Lilly and Teva Pharmaceuticals are going to trial.

A federal appeals court on Monday refused to invalidate three of Teva’s patents for its migraine treatment Ajovy, while also declining to issue a summary judgment in favor of either company, which would effectively end the case without a full trial.

Teva filed suit against Lilly back in 2018, alleging that the company infringed upon nine patents with its rival migraine drug Emgality. The rival drugs were both approved in September 2018 for the preventative treatment of migraine, and are designed to block calcitonin gene-related peptide (CGRP), a protein associated with the onset of migraine pain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Can this tick bi­ol­o­gist and her team of ‘weirdo sci­ence’ en­thu­si­asts change the fu­ture of sci­en­tif­ic re­search?

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

It’s time we talked about bio­phar­ma — live in Lon­don next week

Car­olyn Bertozzi, re­peat biotech founder and launch­er of a field, shares in chem­istry No­bel win

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Pfiz­er, BioN­Tech part­ner with Mar­vel for Avengers and Covid-fight­ing com­ic book

FDA+ roundup: Ad­comm date set for Cy­to­ki­net­ics heart drug; New gener­ic drug guid­ance to re­duce fa­cil­i­ty de­lays

Pen­ny stock, Mer­ck part­ner lays off 45% of staff to reach PhII read­out by ear­ly 2023

Eli Lil­ly and Te­va pre­pare for court bat­tle over mi­graine med ri­val­ry